Blood test provides 'snapshot' of tumor drug response

June 6, 2012

(Medical Xpress) -- Counting the number of tumour cells in blood samples taken before and after treatment for advanced neuroendocrine tumors could provide a ‘snapshot’ of how well patients are responding within weeks of starting treatment, according to results from a study being presented at the American Society for Clinical Oncology cancer conference today (Monday).

The study, coordinated by researchers from the Research UK and NIHR Experimental Cancer Medicine Centre (ECMC) at UCL Cancer Institute, is the largest of its kind and the first to demonstrate how monitoring cancer cells circulating in the blood can be used to predict treatment success for this rare cancer-type, which most commonly affects the gut or pancreas.

Patients found to have circulating tumor cells (CTCs) in the blood at the start of treatment were around eight times more likely to die from their disease, compared to those with undetectable CTC levels.

Study leader Dr. Tim Meyer, who directs UCL ECMC, said: “By using state-of-the-art technology to count individual tumor cells circulating in the blood stream, we’ve been able to show how a simple test could help monitor treatment response and predict how fast the disease will progress. Doctors normally rely on CT or MRI scans to tell them if a treatment is working, but cutting-edge CTC testing can provide an overall snapshot of the tumour’s development, without the need to wait for changes in its size to become visible on scans.

“Although these findings are preliminary, CTC testing is already showing promise in advanced breast, prostate and colorectal cancers and, on the basis of these results, is being incorporated into several trials involving patients with neuroendocrine cancers. This will help uncover ways of determining the impact of treatment on a cellular level, helping tailor treatment to individual patients."

The researchers analysed from 118 patients with advanced neuroendocrine cancers attending the Royal Free Hospital. They compared the numbers of individual present in samples taken before and after treatment.

Patients whose CTC levels fell by more than two thirds within five weeks of starting a new treatment tended to have the best outcomes, while those whose CTC levels rose by more than a third did the worst.

Dr. Joanna Reynolds, Cancer Research UK’s director of centres, said: “This is a great example of how the Experimental Cancer Medicine’s Network is supporting cutting-edge research into rarer cancer types. Advanced cancers often consist of lots of smaller tumours around the body, many of which will be too tiny to be picked up by traditional imaging techniques, making it difficult to judge how well a drug is working. This study highlights a potential way to monitor response in real time across all cancer sites, so doctors know sooner if a isn’t working. Although at an early stage, this is an exciting area of research and we look forward to seeing how it progresses.”

Explore further: Scientists reveal best imaging technique for ovarian cancer

More information:

Related Stories

Scientists reveal best imaging technique for ovarian cancer

February 15, 2012
Cancer Research UK-funded scientists have determined that a magnetic resonance imaging (MRI) technique, which measures the movement of water molecules within the tumour, may be the best way to monitor how women with late-stage ...

'Liquid Biopsy': Blood test gives 'real-time' picture of cancer

May 31, 2012
(Medical Xpress) -- A simple and cost-effective blood test could be used to monitor how a patient is responding to treatment and detect genetic faults in their cancer as they happen, according to a Cancer Research UK study.

Strong evidence supports prognostic value of circulating tumor cells in breast cancer

May 5, 2011
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.

Blood test confirmed to be 'powerful predictor' for metastatic breast cancer following largest analysis to date

May 18, 2011
Researchers at Georgetown Lombardi Comprehensive Cancer Center say the number of circulating tumor cells (CTCs) in the blood is a "powerful predictor" to help physicians more reliably assess treatment benefit for patients ...

Blood test could lead to improved diagnosis and treatment of breast cancer

June 5, 2012
Scientists have discovered that a simple blood test could lead to better diagnosis and treatment for early-stage breast cancer patients, according to an Article published Online First in The Lancet Oncology.

Recommended for you

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Metabolism can be used to subtype hepatoblastoma tumors

September 18, 2017
Looking at cell metabolism instead of histology, EPFL scientists have identified new biomarkers that could help more accurately classify the two main subtypes of hepatoblastoma, a children liver cancer.

Scientists find bacteria in pancreatic tumors that metabolize a common drug

September 15, 2017
To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic ...

New technologies combined to identify specific DNA defect underlying a type of cancer

September 15, 2017
(Medical Xpress)—A team of researchers from the Netherlands and the U.K. has developed a technique for studying inherited types of cancers using two relatively new technologies—organoid development and CRISPR/Cas9. In ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.